Skip to main content

RT @synovialjoints: Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well

Nov 13, 2022 2:30 pm
Social Author Name
Dr. Antoni Chan
Tweet Content
Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well-tolerated over 24 Wks ◦ Improved ESSDAI, salivary flow, Igs ◦ May be first effective oral disease-modifying therapy for SS Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×